U.S. Food and Drug Administration

Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium

2004NationalThyroid : official journal of the American Thyroid Association

United States

Original at the sourceAsk Osler about this guideline

Source and rights

Published by Thyroid : official journal of the American Thyroid Association, 2004. The guideline itself is at the source linked here.

doi.org/10.1089/1050725041517138

Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.

At a glance

Organisation: U.S. Food and Drug Administration
Published: 2004
Applies to: 🇺🇸 United States
Scope: National
Journal: Thyroid : official journal of the American Thyroid Association
DOI: 10.1089/1050725041517138
PubMed: 15307934
Added to Prognia: 23 July 2026

Ask a question about this guideline.

Osler answers from this library and names the guideline behind every claim.

Discover Osler

Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of EndocrinologyWorld Health Organization · 2026Added 23 Jul 2026

Diabetes technology (Update 2026)Wiener klinische Wochenschrift · 2026Added 23 Jul 2026PDF

ISPAD Position Statement on Type 1 Diabetes in SchoolsInternational Society for Pediatric and Adolescent Diabetes · 2026Added 18 Jul 2026PDF

SICOB Italian Clinical Practice GRADE-based guidelines for the endobariatric treatment of overweight, obesity, and obesity-associated diseasesUpdates in surgery · 2026Added 18 Jul 2026PDF

Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD.Dysfunction-Associated Steatotic Liver Disease Working Group · 2026Added 18 Jul 2026PDF

Part 3: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Ultrasound Shear Wave Elastography and MR Elastography Program Implementation, Funding, and Quality AssuranceDysfunction-Associated Steatotic Liver Disease Working Group · 2026Added 18 Jul 2026PDF

Part 1: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Guidance Statements for Detecting and Grading Hepatic Steatosis Using Ultrasound, CT, or MRI.Dysfunction-Associated Steatotic Liver Disease Working Group · 2026Added 18 Jul 2026PDF

Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025Endocrine Society · 2026Added 18 Jul 2026PDF

European Association for the Study of Obesity Position Statement on the Diagnosis and Management of Obesity in Older AdultsObesity facts · 2026Added 18 Jul 2026PDF

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026American Diabetes Association · 2026Added 18 Jul 2026PDF